Marker Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: MRKR · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, filing
TL;DR
Marker Therapeutics held a shareholder vote on 3/21. Expect news soon.
AI Summary
Marker Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on a submission of matters to a vote of security holders that occurred on March 21, 2025. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing indicates that Marker Therapeutics held a shareholder vote, which could pertain to significant corporate actions like mergers, acquisitions, or board changes.
Risk Assessment
Risk Level: medium — Shareholder votes can lead to significant changes in corporate control or strategy, introducing uncertainty.
Key Numbers
- 001-37939 — SEC File Number (Identifies the company's filing history with the SEC.)
- 45-4497941 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former Company Name
- GENEMAX CORP (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Houston, Texas (location) — Principal Executive Offices
- March 21, 2025 (date) — Date of earliest event reported
- March 27, 2025 (date) — Date of Report
FAQ
What specific matters were submitted for a vote by Marker Therapeutics' security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' as the item information, but the specific details of the vote are not provided in this excerpt.
When was the shareholder vote officially held?
The earliest event reported, which corresponds to the date of the shareholder vote, was March 21, 2025.
What is Marker Therapeutics' primary business sector?
Marker Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
What were Marker Therapeutics' previous company names?
Marker Therapeutics was formerly known as TAPIMMUNE INC. and GENEMAX CORP.
Where are Marker Therapeutics' principal executive offices located?
The company's principal executive offices are located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77021.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding Marker Therapeutics, Inc. (MRKR).